<DOC>
	<DOCNO>NCT02406950</DOCNO>
	<brief_summary>Over year , number cardioprotective drug evaluate attenuate lethal ischemia-reperfusion ( IR ) injury . There little study whether sitagliptin protect endothelial dysfunction induce IR injury human .</brief_summary>
	<brief_title>Sitagliptin Endothelial Dysfunction</brief_title>
	<detailed_description>Glucagon-like peptide-1 ( GLP-1 ) novel insulinotropic peptide rapidly degrade enzyme dipeptidyl peptidase-4 ( DPP-4 ) . In addition attractive merit type 2 diabetes , interest cardioprotective effect GLP-1 increase various report evidence . Previously , investigator could show exenatide , GLP-1 receptor agonist protect ischemic/reperfusion injury-induced endothelial dysfunction open KATP ( ATP-sensitive potassium ) channel human ischemic/reperfusion injury model . But , recent clinical study show 2 different DPP-4 inhibitor , alogliptin saxagliptin , decrease major adverse cardiovascular event even though improve glycemic control . The investigator investigate role sitagliptin human ischemic/reperfusion ( IR ) injury model forearm conductance vessel previous describe method .</detailed_description>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>healthy volunteer age 20 40 year nonsmoker High blood pressure ( &gt; 140/90 mmHg ) antihypertensive medication diabetes cardiovascular disease kidney disease thyroid disease cerebrovascular disease liver disease ( bilirubin level &gt; 2 mg/dl ) pregnancy body mass index &gt; 25 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Sitagliptin</keyword>
	<keyword>Endothelium</keyword>
	<keyword>Ischemia-Reperfusion Injury</keyword>
	<keyword>human</keyword>
</DOC>